For every patient, how the disease is treated is a priority. For hyperprolactinemia, drug therapy is preferred, and the commonly used drug of choice is bromocriptine mesylate therapy. This drug has a satisfactory effect in lowering prolactin, shrinking pituitary tumors and restoring pituitary and ovarian functions better. Bromocriptine is taken from small dose The common dose of bromocriptine is 2.5~10mg per day, divided into 2~3 doses, depending on the degree of elevated blood PRL level. Prof. Li reminded that in order to reduce the side effects of the drug, it is necessary to start with a small dose and gradually increase it later, initially 1.25mg each time, 2~3 times a day; taking it with meals can reduce the side effects such as nausea and headache. The dose should be increased by 1.25mg every 3 days, and the PRL value should be measured regularly to adjust the treatment dose individually. Bromocriptine can also be placed in the vagina for patients who cannot tolerate serious side effects. Generally, PRL decreases significantly after two weeks of administration, and overflow stops after 4 weeks of administration. Most patients resume menstruation and ovulation can occur after 3 months of administration. In addition to bromocriptine, quinagolide and vitamin B6 are also available for the treatment of hyperprolactinemia. During the period of taking the medication, it is important to pay attention to the review: 1. Review the PRL level once a month, and the doctor will adjust the medication dose according to the situation. If the PRL level is well controlled for 3 times in a row, it can be changed to once every 6 months; 2. If there is pituitary macroadenoma, MRI and visual field examination of pituitary gland should be done regularly. Do not stop the drug immediately after normal control of prolactin For patients taking bromocriptine treatment, relapse after stopping the drug is a common problem. So how to stop the medication correctly to reduce recurrence? Prof. Li said that once it was believed that lifelong medication was needed, but after years of follow-up investigation, it is now advocated that after the blood prolactin is normalized and the medication is maintained smoothly for 5 years, then bromocriptine can be gradually discontinued to effectively reduce the relapse rate. The relapse rate is the highest in the first year after discontinuation, so it should be reviewed regularly. During the first year of discontinuation, PRL should be rechecked every 3 months, and then every 6 months to 1 year. Once prolactin is found to be elevated again, treatment needs to be started again and a pituitary MRI should be done if necessary. After discontinuation, treatment should still be started at a small dose, with constant dose adjustment. Finally, Prof. Li reminded all mothers-to-be that bromocriptine has no significant toxic side effects on the fetus and does not cause fetal malformations. Since high levels of prolactin in early pregnancy can cause luteal insufficiency and lead to miscarriage. Therefore, it is recommended to stop taking the drug after 2 months of pregnancy when the fetal heart can be heard by ultrasound (fetal survival is basically stable). However, patients with PRL macroadenoma should control their PRL levels and pituitary tumor size before pregnancy. After pregnancy, the status of pituitary tumor should still be closely observed, and the visual field should be reviewed every 2 months, and MRI examination should be performed if necessary. MRI examination does not require contrast agent, does not expose to radiation, and can be performed during pregnancy.